TAILIN BIOTECH(SZ:300813) Zheng Quan Zhi Xing·2025-06-30 16:10Core Viewpoint - The legal opinion letter from Grandall Law Firm confirms that the procedures and results of Zhejiang Tailin Biotechnology Co., Ltd.'s 2025 Second Extraordinary General Meeting of Shareholders are in compliance with relevant laws and regulations [4][11]. Group 1: Meeting Procedures - The meeting was convened following the approval of the proposal to hold the 2025 Second Extraordinary General Meeting by the eighth meeting of the fourth board of directors [5]. - The meeting notice included details such as the time, location, convenor, voting methods, and agenda, ensuring shareholders could attend in person or via proxy [5][6]. - The actual time and location of the meeting matched the notice, and the procedures adhered to the requirements of the Company Law and other relevant regulations [6]. Group 2: Attendance and Voting - A total of 79 participants attended the meeting, representing 68,047,805 shares, which is 56.1454% of the total voting shares [8]. - Among the attendees, 74 were small investors, holding 572,207 shares, accounting for 0.4721% of the total voting shares [8]. - The voting process combined on-site and online methods, with specific time slots for online voting clearly outlined in the meeting notice [6][10]. Group 3: Resolutions and Voting Results - The meeting reviewed and voted on the agenda items as stated in the notice, with the results aligning with the announced agenda [9]. - The voting results showed that 67,957,442 shares were in favor of the resolutions, representing a significant majority of the votes cast [10]. - The resolutions passed were ordinary resolutions, requiring a simple majority for approval, and the results were announced immediately after the voting concluded [10][11].